Seeking Alpha

First patient enrolled in study of BioLineRx's celiac treatment

  • BioLineRx (BLRX +1.8%) enrolls the first patient in a Phase 1/2 study of BL-7010 in celiac disease.
  • Results from the study — which is designed to "assess the safety of single and repeated ascending doses in well-controlled celiac patients" — are due in mid-2014. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector